Abionyx PharmaLTS:0RAG 29 3-Year ROIIC % is 839.31 as of Dec. 2025, which is 10418% above its 10-year median of 7.98. GuruFocus rates LTS:0RAG with a GF Score™ of 29/100 and a GF Value™ of €0.85 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,322 Biotechnology companies, Abionyx Pharma ranks better than 93.57% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Abionyx Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 839.31%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Abionyx Pharma's 3-Year ROIIC % or its related term are showing as below:
LTS:0RAG's 3-Year ROIIC % is ranked better than 93.57% of 1322
companies
in the Biotechnology industry
Industry Median: -4.82
vs LTS:0RAG: 839.31
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Abionyx Pharma 3-Year ROIIC % Related Terms
Abionyx Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Abionyx Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAG vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Abionyx Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abionyx Pharma 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abionyx Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Abionyx Pharma's 3-Year ROIIC % falls into.
Abionyx Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -5.428 (Dec. 2025) - -3.976 (Dec. 2022) )
/
( 11.148 (Dec. 2025) - 11.321 (Dec. 2022) )
=
-1.452
/
-0.173
=
839.31%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Abionyx Pharma (LTS:0RAG) has a 3-Year ROIIC % of 839.31 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Abionyx Pharma and its competitors. This is 10418% above median its historical median of 7.98. According to the industry distribution chart, Abionyx Pharma ranks #85 out of 1322 companies in the Biotechnology industry, placing it in the top 6.4%.
Is Abionyx Pharma's 3-Year ROIIC % too high?
Abionyx Pharma's current 3-Year ROIIC % of 839.31 is 10418% above median its 10-year median of 7.98. Based on the distribution chart, Abionyx Pharma ranks #85 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Abionyx Pharma has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Abionyx Pharma's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abionyx Pharma ranks #85 out of 1322 companies for 3-Year ROIIC %. This places Abionyx Pharma in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Abionyx Pharma and its competitors. Abionyx Pharma's current 3-Year ROIIC % is 839.31, which is 10418% above median its own 10-year median of 7.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abionyx Pharma stock overvalued right now?
Based on GuruFocus' analysis, Abionyx Pharma (LTS:0RAG) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.85, compared to a current price of €1.90 — trading 123.3% above its estimated fair value. The current 3-Year ROIIC % is 839.31, which is 10418% above median its 10-year median of 7.98. Abionyx Pharma's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Abionyx Pharma (LTS:0RAG), the current 3-Year ROIIC % is 839.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abionyx Pharma (LTS:0RAG) Overvalued in 2026?
Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued.
The current stock price of €1.90 is trading 123.3% above its estimated GF Value™ of €0.85.
GuruFocus considers Abionyx Pharma to be Significantly Overvalued.
Key valuation signals for LTS:0RAG:
3-Year ROIIC %: 839.31 (10418% above median its 10-year median of 7.98)
GF Value™: €0.85 vs. price of €1.90 (123.3% above fair value)
No single metric tells the full story. See the LTS:0RAG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
29GF Score
Get the complete analysis for LTS:0RAG
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAG has been successfully added to your 
